Tsedenbal, Batchimeg

Now showing 1 - 2 of 2

Some of the metrics are blocked by your
consent settings
Relationship between Uterine Cervical Cytopathology and Histopathology in Mongolia
(Mongolian National University of Medical Sciences, 2020-04-01)
Uyanga Gotov
;
Batchimeg Tsedenbal
;
Enkhtuya Sharkhuu
;
Dondov Oyunchimeg
;
Bayarmaa Enkhbat
Objectives: This study aimed to evaluate the correlation between uterine cervical squamous cell abnormalities by conventional cytology and corresponding histopathology, and to assess the accuracy between them. Methods: A total of 192 cytological smears of patients with squamous cell abnormalities who underwent colposcopy examination from April – December 2015 were included in this study. The final agreement between cytology and histopathology was defined by the evaluation of histology as a golden standard. Results: The agreement between cytology and histopathology evaluation was 65.6%, and the discrepancy was 33.6% (k=0.512). When the classes of cytology were evaluated for accuracy, it was discovered that NILM* had a higher sensitivity of 77.0%, a specificity of 87.0%, a false positive of 23% and a false negative of 13.0% (k=0.711). Among the LSIL cases a sensitivity was discovered of 39.0%, a specificity of 82.7%, a false positive of 61.0% and a false negative of 17.3% (k=0.392. However, in HSIL sensitivity dropped to 37.8%, specificity increased to 91.6%, false positive were 62.0% and false negative were 8.4% (k=0.501). Conclusion: The agreement for diagnosis of uterine cervical cytology and histopathology was 65.6% (n = 126) and the discrepancy was 33.6% (n = 64) (p = 0.001). The correlation between cervical cytology and histopathology remained moderate (kappa=0.512). Thus, it is proposed that an appropriate quality control system for the cytopathological confirmation may contribute to the further detection and treatment for uterine cervical cancer in Mongolia.
Some of the metrics are blocked by your
consent settings
Influence of tumor mutational burden and immune infiltration on cervical squamous cell carcinoma prognosis
(2026-08-26)
Batchimeg Tsedenbal
;
Battogtokh Chimeddorj
;
Shutao Tan
;
Zhenyong Yang
;
Yunfeng Dai
Introduction: Cervical squamous cell carcinoma (CESC) remains a significant global health challenge for women, necessitating the discovery of precise molecular biomarkers to optimize personalized treatment and immunotherapy strategies. Objective: Leveraging bioinformatics data from The Cancer Genome Atlas (TCGA) and the independent CGCI–HTMCP–CC cohort for external validation, this study rigorously evaluated the prognostic role of tumor mutational burden (TMB) in CESC. Methods: Our methodology utilized standardized transcripts per million (TPM) normalization and the maximally selected rank statistics (maxstat) algorithm to establish biologically optimal TMB thresholds, moving beyond traditional median-based stratification. Results: While somatic mutation analysis identified high frequencies in TTN (29%) and PIK3CA (27%), high TMB levels did not directly correlate with patient overall survival (p = 0.720). However, a marginal non-significant trend was observed between elevated TMB and advanced tumor T-staging (p = 0.057). Differential expression and Cox regression analyses highlighted PTGS2 as a distinctive TMB-related risk gene. Based on this, a TMB-related risk score (TMBRS) was constructed, demonstrating moderate yet consistent predictive utility (area under the curve = 0.696) across both primary and independent validation cohorts. Detailed immune profiling via Cell-type Identification by Estimating Relative Subsets of RNA Transcripts and Tumor Immune Estimation Resource revealed that high TMB and lower risk scores are specifically associated with increased infiltration of CD8+ T cells and M1 macrophages, suggesting enhanced local immune recognition. Conclusion: Although the clinical utility of the TMBRS is currently moderate, this research provides a critical proof of concept for the interplay among PTGS2, mutational load, and the tumor microenvironment, offering valuable mechanistic insights for future large-scale prospective clinical trials.

Tsedenbal, Batchimeg

Filters

Settings

Sort By

Results per page